

CONTENTS

2	CORPORATE INFORMATION
4	FINANCIAL HIGHLIGHTS
6	MANAGEMENT DISCUSSION AND ANALYSIS
14	CORPORATE GOVERNANCE AND OTHER INFORMATION
29	REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION
30	CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
31	CONSOLIDATED STATEMENT OF FINANCIAL POSITION
33	CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
34	CONSOLIDATED STATEMENT OF CASH FLOWS
35	NOTES TO THE UNAUDITED INTERIM FINANCIAL INFORMATION

BOARD OF DIRECTORS

Executive Directors

Mr. C (陳帥)
(Chairman and Acting Chief Executive Officer)
Mr. P C (蒲成川)
M . P J (潘建麗)

Non-executive Directors

M . L L (劉路)
M . N (王楠)

Independent Non-executive Directors

Mr. D J (党金雪)
Mr. L (史錄文)
Mr. (周向亮)

AUDIT COMMITTEE

Mr. (周向亮)(Chairman)
Mr. D J (党金雪)
Mr. L (史錄文)

REMUNERATION COMMITTEE

Mr. D J (党金雪)(Chairman)
Mr. P C (蒲成川)
Mr. (周向亮)

NOMINATION COMMITTEE

Mr. C (陳帥)(Chairman)
Mr. D J (党金雪)
Mr. L (史錄文)

COMPANY SECRETARY

M . H (何詠欣)(ACG, HKACG (PE))

AUTHORISED REPRESENTATIVES

Mr. C (陳帥)
M . H (何詠欣)(ACG, HKACG (PE))

LISTING INFORMATION AND STOCK CODE

E H K L
(Stock Exchange)
 C : 3869

HEAD OFFICE IN THE PEOPLE'S REPUBLIC OF CHINA

H C r r C L (, Company ,
r , Group , we , our
us.)
4 F r , A r C C r P
N .40 , , C D r , B
P , C (PRC)

**PRINCIPAL PLACE OF BUSINESS
IN HONG KONG**

10, 70/F
 100, 70/F
 No. 8F
 100, 70/F
 Hong Kong

**HONG KONG BRANCH SHARE REGISTRAR
AND TRANSFER OFFICE**

100, 70/F
 1712-1716, 17/F
 183
 Hong Kong

REGISTERED OFFICE

100, 70/F
 POB 309, 100, 70/F
 Grand Canal, K 1-1104
 Cayman Islands

**CAYMAN ISLANDS PRINCIPAL SHARE
REGISTRAR AND TRANSFER OFFICE**

COMPANY'S WEBSITE

www.100.com.hk

AUDITOR

KPMG
*Public Interest Entity Auditor registered in accordance
 with the Accounting and Financial Reporting Council
 Ordinance*

		Six months ended June 30,	
		2023	2022
		RMB'000	MB'000
		(Unaudited)	()
		717,831	540,918
H	r	36,852	43,097
G	r r	674,192	492,965
	r r	6,787	4,856
A	r r (1)	131,568	82,323
A	r (2)	60,893	43,393
A	r r r	18.3%	15.2%
A	r r	8.5%	8.0%
Adjusted items			
E	r - r		
	(2)(i)	270	1,674
N	r r		
	r (2)(ii)	(128,438)	32,834
D	r r		
	(2)(iii)	11,145	10,260
	r		
	r r r		
	r	-	435,918
		717,831	540,918
Gr	r (1)	120,153	72,155
N	r /() (2)	177,916	(437,293)
B	r /() r r (MB)	0.91	(3.09)

Notes:

BUSINESS REVIEW AND PROSPECTS

Policy review

I r 2023, r r H
C r , r r - C O
r C r r . G r O r C O

Strengthening medical quality control and promoting management refinement

In 2023, ... Three-step (Group Hospital(s)) ... Gr

Gr ... H ... Gr ...

In ... Gr ... H ...

Strengthening of the anti-corruption system and standardization of supply chain development

Gr ... - ...

A ... Gr ... Fr ... Gr H ...

In 2023 ... COVID-19 ... Gr ... C ... Gr ...

FINANCIAL REVIEW

Results of Operations

<p> D r r P r , r r r r r MB717.8 , r r r r r r 32.7% r r MB540.9 C r r P r P r r , r r r r r r r r r r r H *(上海楊思醫院)(Yangsi Hospital) </p>	<p> O r r r r r r r r r r r r r C H H *(慈溪弘和醫院)(Cixi Hospital) J G O H (Jinhua Hospital). D r r P r , r r MB36.9 , r r r r r 14.5% r MB43.1 C r r P r P r r , r r r r J H r MB5.0 </p>
<p> D r r P r , r r r r r r r r r r r 36.8% r MB674.2 r r MB493.0 C r r P r P r r , r r r r r r r r r H </p>	<p> O r r r r r MB131.6 r r P r , r r - r r r r , r r r r r 59.8% r r MB82.3 r C r r P r P r r . r r r r r r r H </p>
<p> r r r r r MB49.2 r r P r , r r r r 46.9% r r MB33.5 r C r r P r P r r , r r r r r r C r r P r P r r </p>	<p> r r r r r MB83.6 r r P r , r r r r MB29.9 r r MB53.7 r C r r P r P r r . r r r r r r r r r H </p>
<p> F r r P r , r r r A N P r r MB60.9 , r r r r 40.3% r A N P r r MB43.4 C r r P r P r r . , r r r r r r r r r H </p>	

LIQUIDITY AND CAPITAL RESOURCES

As at June 30, 2023, the Group's cash and cash equivalents were RMB624.0 million (December 31, 2022: RMB443.4 million). As at June 30, 2023, the Group's short-term deposits were RMB861.8 million (December 31, 2022: RMB843.0 million). As at June 30, 2023, the Group's long-term deposits were RMB1,785.7 million (December 31, 2022: RMB723.8 million). The Group's average cash and cash equivalents turnover ratio was 1.19 times (December 31, 2022: 0.47 times).

As at June 30, 2023, the Group's other receivables were RMB18.8 million (December 31, 2022: RMB843.0 million). As at June 30, 2023, the Group's other payables were RMB861.8 million (December 31, 2022: RMB1,062.0 million). As at June 30, 2023, the Group's other assets were RMB1,785.7 million (December 31, 2022: RMB723.8 million).

As at June 30, 2023, the Group's prepayments were RMB46.6 million (December 31, 2022: RMB69.4 million). As at June 30, 2023, the Group's other liabilities were RMB592.9 million (December 31, 2022: RMB497.1 million).

As at June 30, 2023, the Group's total assets were RMB1,785.7 million (December 31, 2022: RMB1,062.0 million). As at June 30, 2023, the Group's total liabilities were RMB592.9 million (December 31, 2022: RMB497.1 million).

Bank borrowings

	As at June 30, 2023	December 31, 2022
	RMB'000	RMB'000
Bank borrowings	46,600	69,429

As at June 30, 2023, the Group's bank borrowings were RMB46.6 million (December 31, 2022: RMB69.4 million). The Group's bank borrowings were denominated in RMB. As at June 30, 2023, the Group's bank borrowings were secured by RMB1,785.7 million (December 31, 2022: RMB723.8 million) of cash and cash equivalents. The Group's bank borrowings were denominated in RMB. As at June 30, 2023, the Group's bank borrowings were secured by RMB1,785.7 million (December 31, 2022: RMB723.8 million) of cash and cash equivalents. The Group's bank borrowings were denominated in RMB. As at June 30, 2023, the Group's bank borrowings were secured by RMB1,785.7 million (December 31, 2022: RMB723.8 million) of cash and cash equivalents.

On March 27, 2022, the Company entered into a loan agreement (the **Guarantee Agreement**) with Nanyang Commercial Bank (China) Limited Beijing Branch (the **Bank**), for the purpose of providing a corporate guarantee to Jinhua Guangfu Hospital (浙江金華廣福腫瘤醫院, Hubei Medical Co., Ltd. (浙江弘和致遠醫療科技有限公司) (Zhiyuan Medical)) (Jinhua Guangfu Hospital Corporate Guarantee). The Company's guarantee is provided to the Bank on behalf of the Jinhua Guangfu Hospital. The loan agreement is for a term of 12 months, with a principal amount of RMB50 million. The interest rate is 4.79% per annum. The Company's guarantee is provided to the Bank on behalf of the Jinhua Guangfu Hospital. The loan agreement is for a term of 12 months, with a principal amount of RMB50 million. The interest rate is 4.79% per annum. The Company's guarantee is provided to the Bank on behalf of the Jinhua Guangfu Hospital.

As of December 31, 2022, the Company has provided a corporate guarantee of RMB50 million to the Bank on behalf of the Jinhua Guangfu Hospital. The loan agreement is for a term of 12 months, with a principal amount of RMB50 million. The interest rate is 4.79% per annum. The Company's guarantee is provided to the Bank on behalf of the Jinhua Guangfu Hospital.

On July 24, 2019, the Company entered into a loan agreement (the **Existing 2019 Loan Agreement**) with Jinhua Guangfu Hospital, for the purpose of providing a loan to the Company. The loan agreement is for a term of 36 months, with a principal amount of RMB80 million. The interest rate is 5.23% per annum. The Company's loan is provided to the Bank on behalf of the Jinhua Guangfu Hospital. The loan agreement is for a term of 36 months, with a principal amount of RMB80 million. The interest rate is 5.23% per annum. The Company's loan is provided to the Bank on behalf of the Jinhua Guangfu Hospital.

On November 20, 2020, the Company entered into a loan agreement (the **Existing 2020 Loan Agreement**) with Tibet Honghe Zhiyuan Co., Ltd. (西藏弘和志遠企業管理有限公司) (Tibet Honghe Zhiyuan), for the purpose of providing a loan to the Company. The loan agreement is for a term of 36 months, with a principal amount of RMB100 million. The interest rate is 4.79% per annum. The Company's loan is provided to the Bank on behalf of the Tibet Honghe Zhiyuan Co., Ltd. The loan agreement is for a term of 36 months, with a principal amount of RMB100 million. The interest rate is 4.79% per annum. The Company's loan is provided to the Bank on behalf of the Tibet Honghe Zhiyuan Co., Ltd.

The Company has provided a corporate guarantee of RMB50 million to the Bank on behalf of the Jinhua Guangfu Hospital. The loan agreement is for a term of 12 months, with a principal amount of RMB50 million. The interest rate is 4.79% per annum. The Company's guarantee is provided to the Bank on behalf of the Jinhua Guangfu Hospital.

As at December 31, 2022, the carrying amount of the Group's convertible bonds is HK\$14 million. The Group's convertible bonds are issued at a fixed rate of 5% and have a maturity date of December 27, 2022. The Group's convertible bonds are classified as financial liabilities.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group has no material acquisitions or disposals of subsidiaries, associates and joint ventures during the reporting period ended December 31, 2023.

CONNECTED TRANSACTION ON EXTENSION OF MATURITY DATE OF CONVERTIBLE BONDS

On January 6, 2023, the Group's convertible bonds (Vanguard Glory Convertible Bonds) issued on March 5, 2018, were extended from December 29, 2023 to December 30, 2025. The extension of the maturity date was approved by the holders of the Vanguard Glory Convertible Bonds.

As at December 31, 2022, the carrying amount of the Group's convertible bonds (Hony Fund VIII Convertible Bonds) issued on July 7, 2018, was HK\$773,879,717. The Group's convertible bonds were extended from December 31, 2022 to December 30, 2025. The extension of the maturity date was approved by the holders of the Hony Fund VIII Convertible Bonds.

The Group's convertible bonds (Vanguard Glory Convertible Bonds) are classified as financial liabilities. The carrying amount of the Group's convertible bonds is HK\$18.00 million as at December 31, 2022, and HK\$773,879,717 as at December 31, 2023.

The Group's convertible bonds (Hony Fund VIII Convertible Bonds) are classified as financial liabilities. The carrying amount of the Group's convertible bonds is HK\$20.00 million as at December 31, 2022, and HK\$773,879,717 as at December 31, 2023.

The Group's convertible bonds (Vanguard Glory Convertible Bonds) are classified as financial liabilities. The carrying amount of the Group's convertible bonds is HK\$18.00 million as at December 31, 2022, and HK\$773,879,717 as at December 31, 2023.

A A E E D C

A D A A

r r G r A r r r H F A r r r
r r C r r r r r , I r r r'
r r r r C r 14A L .

r r r r r r J 31, 2023 r r
r r G r D A , r r G r A r r r r ,
H F D A , H F A r r r r r , r r
r r r r C r r r
H F C r B . r r G r C r B

F r r r G r C r B H C r B , r r r
r r C J 7, 2023 r r C J
6, 2023.

A J 30, 2023, C r r r r r r r
 r MB50.0 J H N
 C r B (C) L , B Br . A J 30, 2023, r
 J H MB40.0 .

☒ , J 30, 2023 D r 31, 2022, Gr
 r r r , r N 18 r .

INTERIM DIVIDEND

B r r r r r r J 30, 2023.

HUMAN RESOURCES

A J 30, 2023, 1,437 (J 30, 2022: 1,393). r ,
 -r r r r r r r r r
 r , r . F r J 30, 2023,
 (Dr r r r) r r MB205.2 (r
 J 30, 2022: r MB166.9).

r r r r r r r r r , r r r
 r r r . r r r r r r r r r , r r
 r r r . A r r P C r , r r r r

DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES,

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As of June 30, 2023, the following table sets forth the substantial shareholders' interests and short positions in the Shares and underlying Shares of the Company. The information is based on the records maintained by the Company and the information provided by the substantial shareholders. The Company has not received any notification of any change in the substantial shareholders' interests and short positions in the Shares and underlying Shares of the Company since June 30, 2023.

Long positions in the Shares and underlying Shares of the Company

Name of Shareholder	Capacity/Nature of interest	Number of Shares or underlying Shares of the Company	Approximate percentage of shareholding interest ⁽⁶⁾
▼ H C F (1)	B	123,000,000	89.01%
H C F L.P. ⁽²⁾	I	123,000,000	89.01%
H C F GP, L.P. ⁽²⁾	I	123,000,000	89.01%
H C F GP L ⁽²⁾	I	123,000,000	89.01%
H Gr M L ⁽²⁾⁽³⁾	I	161,693,985	117.01%
H M P r r L ⁽²⁾⁽³⁾	I	161,693,985	117.01%
E F r	I	161,693,985	117.01%
Gr L ⁽²⁾⁽³⁾			
H F III ⁽³⁾	B	38,693,985	28.00%
H C F III GP (C), L.P. ⁽³⁾	I	38,693,985	28.00%
H C F III GP (C) L ⁽³⁾	I	38,693,985	28.00%
Mr. J H ⁽⁴⁾	I	161,693,985	117.01%
A ' LP ⁽⁵⁾	B	9,098,800	6.58%
A ' ⁽⁵⁾	I	9,098,800	6.58%
H K C	I	9,098,800	6.58%
M P r r (L P r r) (合肥康養資本管理合夥企業 (有限合夥)) ⁽⁵⁾			
A C E I F M C ., L . (安徽創谷股權投資基金管理 有限公司) ⁽⁵⁾	I	9,098,800	6.58%
Mr. N ⁽⁵⁾	I	9,098,800	6.58%

- (1) ... GP ... H F ... L.P. ... 97,000,000 ... C
 ... 26,000,000 ... C
 ... 18.81% ... C ... J 30, 2023. F ... ,
 ... C ... B ...
- (2) H C F ... L.P. ... H C F ... L.P. H C F ... GP, L.P.,
 ... H C F ... GP L ... H C F ... GP L ... H Gr
 M ... L ... , 80% ... H M P ... L ... ,
 E ... F ... Gr L ... E ... F ... Gr L ... 49% Mr. J
 H . Mr. J H ... H C F ... GP L ... , H Gr M ... L ... , H
 M P ... L ... E ... F ... Gr L ...
- (3) H C F ... III (C ...), L.P. ... H C F ... III (C ...), L.P. H C F ... III GP
 (C ...), L.P., ... H C F ... III GP (C ...) L ... H C F ... III GP
 (C ...) L ... H Gr M ... L ... , 80% ... H
 M P ... L ... , ... E ... F ... Gr L ... E ... F ...
 Gr L ... 49% Mr. J H . Mr. J H ... H C F ... III
 GP (C ...) L ... , H Gr M ... L ... , H M P ... L ... E ... F ... III
 Gr L ...
- (4) Mr. J H ... 161,693,985 ... C ...
 ... GP ... H F ... III. ... GP ... 97,000,000 ... C
 ... C ... -1.5 760 10 B 275 (...) 4 L ... - ...) 0.5 ... C

CONVERTIBLE BONDS

Vanguard Glory Convertible Bonds

In 2018, the Group issued Vanguard Glory Convertible Bonds with a face value of HK\$468 million, convertible into shares of the Company at a conversion price of HK\$18.00 per share. The bonds were issued at a discount of 70.19% to the face value. The bonds were issued on June 25, 2018, and mature on March 5, 2018. The Group has a carrying amount of 26,000,000 for these bonds.

On December 17, 2020, the Group issued Vanguard Glory Convertible Bonds with a face value of HK\$18.00 million, convertible into shares of the Company at a conversion price of HK\$18.00 per share. The bonds were issued at a discount to the face value. The Group has a carrying amount of 18,000,000 for these bonds. (Alteration of Terms).

Pursuant to the terms of the Vanguard Glory Convertible Bonds, the Group has a carrying amount of 3,111,611 for these bonds as of March 5, 2021.

C A E E A C E A D E A

HK\$467 HK\$405
 H M M C., L. (Cixi Hongai) M 2018. A J 30, 2023,
 HK\$62 Gr
 H K,
 C F 13, 2018 (Circular).
 Gr
 Dr C
 .D P
 B Cr. A J 30, 2023,

	Intended use of net proceeds	Revised use of unutilized net proceeds	Utilized amount subsequent to December 31,			Expected time period
			Utilized amount up to December 31, 2022	2022 and up to June 30, 2023	Unutilized amount as at June 30, 2023	
	Pr HK\$	Pr HK\$	Pr HK\$	Pr HK\$	Pr HK\$	
A C H	211	45% 405	87% 405			
A						
	256	55% 62	13%		62	2023
	467	100% 467	100%	405	62	

A J 30, 2023,
 C .D
 C J 25, 2018, J 6, 2023 F 13, 2018 J 7, 2023,

Dilu i Im ac Ea Ag e Sha e

A J 30, 2023, MB126.2
 C MB0.02. MB0.91

On June 6, 2023, the Board of Directors of the Company approved the 2023 Annual Report of the Company, including the financial statements, and authorized the Board of Directors to publish the 2023 Annual Report of the Company on the Company's website and the Hong Kong Stock Exchange website, and to provide the 2023 Annual Report of the Company to the Hong Kong Stock Exchange and the Securities and Futures Commission.

The 2023 Annual Report of the Company is available on the Company's website (www.hospital.com.hk) and the Hong Kong Stock Exchange website (www.hkex.com.hk) from June 7, 2023 to June 30, 2025.

The Board of Directors of the Company is pleased to announce that the 2023 Annual Report of the Company will be published on June 7, 2023.

The Board of Directors of the Company is pleased to announce that the 2023 Annual Report of the Company will be published on June 7, 2023.

Dilip Limac Eashe Sha e

A copy of the 2023 Annual Report of the Company is available on the Company's website (www.hospital.com.hk) and the Hong Kong Stock Exchange website (www.hkex.com.hk) from June 7, 2023 to June 30, 2025.

The Board of Directors of the Company is pleased to announce that the 2023 Annual Report of the Company will be published on June 7, 2023.

Date **September 30, 2025**
(HK\$)

20.0

LW Convertible Bonds

On June 16, 2019, the Company issued convertible bonds with a principal amount of HK\$800,000,000 (the "LW Convertible Bonds"). The bonds are convertible into shares of the Company at a conversion price of HK\$1.00 per share. The bonds have a maturity date of June 27, 2019, and a coupon rate of 6% per annum. The bonds are convertible into shares of the Company at the option of the bondholders. The bonds are convertible into shares of the Company at a conversion price of HK\$1.00 per share. The bonds have a maturity date of June 27, 2019, and a coupon rate of 6% per annum. The bonds are convertible into shares of the Company at the option of the bondholders.

On June 16, 2019, the Company issued convertible bonds with a principal amount of HK\$16.18 million. The bonds are convertible into shares of the Company at a conversion price of HK\$16.18 per share.

On August 12, 2021, the Company issued convertible bonds with a principal amount of HK\$16.18 million (the "Early Redemption"). The bonds are convertible into shares of the Company at a conversion price of HK\$16.18 per share.

On August 8, 2021, the Company issued convertible bonds with a principal amount of HK\$16.18 million. The bonds are convertible into shares of the Company at a conversion price of HK\$16.18 per share.

r L C r B :

() r r r r r r r :

r r r C B r, C r B
r C r r M r D r E r
A r r :

E r A = Pr C r B r
98%.

() r r r r r r r :

r r r C B r, r r ,
C E r A B r .
r C B r r
A r C B r . N r r E r
r , r C r
r , r (. . 5% r) r r
r C r B .

O O r 15, 2021, C r r r L r r r
r L C r B r HK\$800,000,000, r
, C r r , HKD784,000,000, L
r :

Payment dates	Instalment amount (HKD)
O r 20, 2021	550
J 31, 2022	120
J 31, 2023	114
E r A :	<u>784</u>

C HKD695 r r, HKD89 r
r .

F r r L C r B , r r L
C r B L C r B r r r
r r , L C r B
C r r r r r L
C r B .

Dilution Effect of the Conversion of the Vanguard Glory Convertible Bonds, the Hony Convertible Bonds and the LW Convertible Bonds

Substantial Shareholders	As at June 30, 2023		Immediately upon full conversion of the Vanguard Glory Convertible Bonds and the Hony Convertible Bonds	
	Number of Shares	Percentage	Number of Shares	Percentage
Vanguard Glory Convertible Bonds	97,000,000	70.19	123,000,000	60.62
Hony Convertible Bonds	0	0.00	38,693,985	19.07
LW Convertible Bonds	9,098,800	6.58	9,098,800	4.48

Note: The above table is based on the assumption that all convertible bonds are converted into shares of the Company at the end of the reporting period. The actual dilution effect may vary due to the timing of conversions and other factors.

SHARE-BASED PAYMENT SCHEMES

(a) Pre-IPO Share Appreciation Rights Scheme

On November 28, 2016, the Board of Directors of the Company approved the Pre-IPO SARs Scheme. The Pre-IPO SARs are granted to eligible employees of the Company. The Pre-IPO SARs are exercisable from the date of grant to the date of the IPO. The Pre-IPO SARs are exercisable at a price of HK\$0.01 per share. The Pre-IPO SARs are exercisable for a maximum of 2,500,000 shares.

As at December 31, 2016, the number of Pre-IPO SARs granted to eligible employees of the Company was 2,500,000. The Pre-IPO SARs are exercisable from the date of grant to the date of the IPO.

As at December 31, 2017, the number of Pre-IPO SARs granted to eligible employees of the Company was 2,500,000. The Pre-IPO SARs are exercisable from the date of grant to the date of the IPO.

As at December 31, 2019, the number of Pre-IPO SARs granted to eligible employees of the Company was 2,500,000. The Pre-IPO SARs are exercisable from the date of grant to the date of the IPO.

C A E E A C E A D E A

Fr	M r	15, 2019,	, r r	25%	r	r , r
r		. l 2019,	r	Pr -IPO SA	Gr	r r 50%
-		r r	r	Pr -IPO SA		.
Fr	M r	15, 2020,	r , r r	25%	r	r , r r
		.				
Fr	M r	15, 2021,	, r r	25%	r	r , r r
		.				

(c) Post-IPO Share Appreciation Rights Scheme

On 13, 2016, the Company adopted a Post-IPO SARs Scheme (the "Post-IPO SARs Scheme") for its employees. The Post-IPO SARs Scheme is a long-term incentive plan designed to attract and retain key employees and to reward their contributions to the Company's success. The Post-IPO SARs Scheme is a non-qualified plan and is subject to the Internal Revenue Code and applicable state laws. The Post-IPO SARs Scheme is administered by the Compensation Committee of the Board of Directors (the "Compensation Committee").

The Post-IPO SARs Scheme is available to all full-time employees of the Company who are at least 21 years of age and who are not subject to a non-compete agreement. The Post-IPO SARs Scheme is subject to the following terms and conditions:

- The Post-IPO SARs Scheme is a non-qualified plan and is subject to the Internal Revenue Code and applicable state laws.
- The Post-IPO SARs Scheme is administered by the Compensation Committee of the Board of Directors.
- The Post-IPO SARs Scheme is available to all full-time employees of the Company who are at least 21 years of age and who are not subject to a non-compete agreement.
- The Post-IPO SARs Scheme is subject to the following terms and conditions:
 - The Post-IPO SARs Scheme is a long-term incentive plan designed to attract and retain key employees and to reward their contributions to the Company's success.
 - The Post-IPO SARs Scheme is a non-qualified plan and is subject to the Internal Revenue Code and applicable state laws.
 - The Post-IPO SARs Scheme is administered by the Compensation Committee of the Board of Directors.
 - The Post-IPO SARs Scheme is available to all full-time employees of the Company who are at least 21 years of age and who are not subject to a non-compete agreement.
 - The Post-IPO SARs Scheme is subject to the following terms and conditions:
 - The Post-IPO SARs Scheme is a long-term incentive plan designed to attract and retain key employees and to reward their contributions to the Company's success.
 - The Post-IPO SARs Scheme is a non-qualified plan and is subject to the Internal Revenue Code and applicable state laws.
 - The Post-IPO SARs Scheme is administered by the Compensation Committee of the Board of Directors.
 - The Post-IPO SARs Scheme is available to all full-time employees of the Company who are at least 21 years of age and who are not subject to a non-compete agreement.

A r r r r, A r r 592,000 r r r
 A r r r r r 0.43% r C
 r r r r r r r r r r r
 13,227,400, r r r 9.57% r C
 r r r r.

r r r A r r E P r r r
 r r r r r r r r (r r r
 r r r r r) 12- r r
 r r r r r r 1% r C r r
 r r r r r r C r r r r r r P r
 / r r (r r r r) r r r
 C r r r r r r r.

r r r A r r 12 .

F r r r A r r C
 J r r 18, 2021.

PUBLIC FLOAT

B r r r, C r r r r r r r r r L
 25%.

CHANGES TO DIRECTORS' INFORMATION

D r r r r r r r r 13.51B(1) L

COMPLIANCE WITH CORPORATE GOVERNANCE CODE

C A 14 L .E r r C r r G r r C (CG Code)
 r P r r, C r r r r r r r r CG C .
 C r r r r r r r r r r r
 CG C .

Pr C.2.1 CG C
 Mr. SHAN G
 (Chief Executive Officer)
 Mr. HAO J H
 , Mr. CHEN (Mr. CHEN)
 Mr. CHEN
 Mr. CHEN
 C.2.1 CG C
 Mr. CHEN C
 E O
 C

COMPLIANCE WITH MODEL CODE

C
 Dr (Securities
 Dealing Code)
 A 10 L . H
 M C
 D C
 P

AUDIT COMMITTEE

Gr Pr
 A C A C Dr ,
 Mr. HO (C) Mr. SHI L , Mr. DANG J . A C
 L

PURCHASE, SALE AND REDEMPTION OF THE COMPANY'S LISTED SECURITIES

592,000
 Pr C
 C

FINANCIAL INFORMATION

Gr ' r r r J 30, 2023
 Gr ' r r , KPMG, A C



Review report to the board of directors of Hospital Corporation of China Limited

(Incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have been engaged by the board of directors of Hospital Corporation of China Limited (the "Company") to review the financial statements of the Company for the period from 30 June 2023 to 30 June 2023. The financial statements are set out in pages 62 to 63 of the Interim Report of the Company. The financial statements are prepared in accordance with the Accounting Standards for Private Enterprises in China (ASPEs) and the applicable laws and regulations of the Cayman Islands. The financial statements are presented in Chinese and English. The English version of the financial statements is the authoritative version for the purpose of this review report.

Our review was conducted in accordance with the standards of the Institute of Certified Public Accountants of China (ICPA) and the applicable laws and regulations of the Cayman Islands. We have not performed an audit and we do not express an opinion on the financial statements. Our review is limited to the review of the financial statements and does not extend to the internal control system of the Company. We have not performed any procedures to identify any fraud or other illegal acts. Our review is also limited to the financial statements and does not extend to the operations of the Company.

Our review was conducted in accordance with the standards of the Institute of Certified Public Accountants of China (ICPA) and the applicable laws and regulations of the Cayman Islands. We have not performed an audit and we do not express an opinion on the financial statements. Our review is limited to the review of the financial statements and does not extend to the internal control system of the Company. We have not performed any procedures to identify any fraud or other illegal acts. Our review is also limited to the financial statements and does not extend to the operations of the Company.

C O R P O R A T I O N A C C O U N T S

for the six months ended 30 June 2023 – unaudited
(Expressed in Renminbi (“RMB”))

		Six months ended 30 June	
		2023	2022
		RMB'000	MB'000
	N		
Revenue	5	717,831	540,918
C		(597,678)	(468,763)
Gross profit		120,153	72,155
A		(49,200)	(35,267)
Ⓜ		(631)	(282)
N		–	(662)
I		–	(460,283)
O		8	3,833
O	6	129,904	(35,062)
Operating profit/(loss)		200,234	(455,568)
F	7	4,360	8,094
F	7	(3,622)	(4,089)
Profit/(loss) before income tax		200,972	(451,563)
I	8	(23,056)	14,270
Profit/(loss) for the period		177,916	(437,293)
Other comprehensive income			
Item that will not be subsequently reclassified to profit or loss			
r		7,358	(2,527)
Total comprehensive income for the period		185,274	(439,820)
Attributable to:			
O		126,218	(427,562)
N		59,056	(12,258)
Total comprehensive income for the period		185,274	(439,820)
Earnings/(Losses) per share from profit/(loss) attributable to owners of the Company			
B	9	0.91	(3.09)
D	9	(0.02)	(3.09)

35 62 r r r r .

ASSETS

Non-current assets

Prepaid expenses and other receivables
1(MB'000) ,93310

N

10

30 June
2023
RMB'000

31 D
2022
MB'000

196,671

218,933

as at 30 June 2023 – unaudited
(Expressed in RMB)

		30 June 2023 RMB'000	31 D 2022 MB'000
	N		
LIABILITIES			
Non-current liabilities			
C r	19	895,259	
L	11	6,592	6,240
E		45,568	49,111
D r	20	149,473	151,056
		<u>1,096,892</u>	<u>206,407</u>
Total non-current liabilities			
Current liabilities			
r	16	131,956	136,855
C r	19	–	1,026,407
A r , r	17	520,222	520,757
A r r	14	7,661	10,757
C r		1,794	2,148
C r		13,988	17,849
B r	18	46,600	69,429
L	11	1,556	1,527
		<u>723,777</u>	<u>1,785,729</u>
Total current liabilities			
Total liabilities			
		<u>1,820,669</u>	<u>1,992,136</u>
Total equity and liabilities			
		<u>2,444,691</u>	<u>2,435,564</u>

	Attributable to owners of the Company							Total equity RMB'000
	Share capital RMB'000	Share premium RMB'000	Other reserves RMB'000	Treasury shares RMB'000	Accumulated losses RMB'000	Sub-total RMB'000	Attributable to non-controlling interests RMB'000	
Balance at 1 January 2023	123	435,304	870,779	-	(1,050,496)	255,710	187,718	443,428
Change during the period								
- Issuance of shares	-	-	-	-	126,218	126,218	51,698	177,916
- Share repurchase	-	-	-	-	-	-	7,358	7,358
- Share repurchase (N/A)	-	-	-	(4,680)	-	(4,680)	-	(4,680)
Balance at 30 June 2023	123	435,304	870,779	(4,680)	(924,278)	377,248	246,774	624,022
Balance at 1 January 2022	123	435,304	929,345		(566,799)	797,973	337,854	1,135,827
Change during the period								
- Loss					(427,562)	(427,562)	(9,731)	(437,293)
- Share repurchase							(2,527)	(2,527)
- Share repurchase			128			128		128
- Dividend			(61,445)			(61,445)	(57,555)	(119,000)
- Dividend							(12,000)	(12,000)
Balance at 30 June 2022	123	435,304	868,028		(994,361)	309,094	256,041	565,135

Notes: As at 30 June 2023, the Company has 592,000 shares outstanding, representing 62.5% of the total shares of 947,000 shares.



1 GENERAL INFORMATION

Head Office: 21st Floor, 2014, 1961, PO Box 309, ...

Company information, registered office, and other details.

Company name in Chinese and English, and other identifying information.

2 BASIS OF PREPARATION

Interim financial reporting, 30 June 2023, and related accounting standards.

Financial statements for 2022 and 2023, and the auditor's opinion.

Additional financial reporting details, including interim financial statements and related disclosures.

(Expressed in RMB unless otherwise indicated)

2 BASIS OF PREPARATION

KPMG 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, 29.

31 D 2022 Gr C 27 M 2023.

3 CHANGES IN ACCOUNTING POLICIES

Gr IF IASB
IF 17, Insurance contracts
IAS 8, Accounting policies, changes in accounting estimates and errors: Definition of accounting estimates
IAS 12, Income taxes: Deferred tax related to assets and liabilities arising from a single transaction
IAS 12, Income taxes: International tax reform - Pillar Two model rules
Gr IF
N IF Gr

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

(a) Financial assets and liabilities measured at fair value

(i) Fair value hierarchy

The fair value hierarchy is based on the following categories:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the asset or liability; and market-corroborated inputs.

Level 3: Inputs that are not based on observable market data.

Grading: A

As at 30 June 2023

As at 31 December 2022

	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
As at 30 June 2023				
Asset				
Financial assets measured at fair value				
Financial assets at fair value through profit or loss (FVPL)				
Monetary assets	-	70,865	-	70,865
Total asset	-	70,865	-	70,865
Liability				
Financial liabilities measured at fair value				
Financial liabilities at fair value through profit or loss (FVPL)				
Contractual liabilities (N/A)	-	-	895,259	895,259
Total financial liability	-	-	895,259	895,259
As at 31 December 2022				
Asset				
Financial assets measured at fair value				
Financial assets at fair value through profit or loss (FVPL)				
Monetary assets		129,848		129,848
Total asset		129,848		129,848
Liability				
Financial liabilities measured at fair value				
Financial liabilities at fair value through profit or loss (FVPL)				
Contractual liabilities (N/A)			1,026,407	1,026,407
Total financial liability			1,026,407	1,026,407

(Expressed in RMB unless otherwise indicated)

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS c ~~Fixed~~

(a) Financial assets and liabilities measured at fair value c ~~Fixed~~

(i) Fair value hierarchy c ~~Fixed~~

	r	r	r	r	1,2	3	r	r	r
Gr				r	r	r	r	r	r
				r	r	r			r

L 1:

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

(a) Financial assets and liabilities measured at fair value

(iii) Fair value measurement using significant observable inputs (level 2)

	2023	2022
Opening balance as at 1 January 2023	129,848	129,848
Acquisition	9,172	9,172
Disposal	(70,135)	(70,135)
Gain/(loss)	1,980	1,980
Closing balance as at 30 June 2023	70,865	70,865

**Monetary funds
RMB'000**

(i) Fair value measurement using significant unobservable inputs (level 3)

	2023	2022
Opening balance as at 1 January 2023	(1,026,407)	(1,026,407)
Gain/(loss), *	131,148	131,148
Closing balance as at 30 June 2023	(895,259)	(895,259)

**Convertible bonds
(Note 19)
RMB'000**

	2023	2022
Opening balance as at 1 January 2023	131,148	131,148
Gain/(loss)	-	-
Closing balance as at 30 June 2023	131,148	131,148

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS ~~c~~ ~~Amended~~

(a) Financial assets and liabilities measured at fair value ~~c~~ ~~Amended~~

(i) Fair value measurement using significant ~~unobservable~~ ~~inputs~~ (level 3) ~~c~~ ~~Amended~~

() C r

M r r r

(Expressed in RMB unless otherwise indicated)

5 SEGMENT INFORMATION c ~~i~~ ~~u~~ ~~e~~ ~~d~~

(d) Unallocated

☐

Gr

	General hospital services RMB'000	Hospital management services RMB'000	Sale of pharmaceutical products RMB'000	Elimination RMB'000	Unallocated RMB'000	Total RMB'000
Six months ended 30 June 2023	676,192	82,945	6,787	(48,093)	-	717,831
	(2,000)	(46,093)	-	48,093	-	-

5 SEGMENT INFORMATION *c* ~~1~~ ~~1~~ *ued*

(d) Unallocated *c* ~~1~~ ~~1~~ *ued*

	Gr 89	89	H 89	9	9	8
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000
Six months ended 30 June 2022						
Gr 9r	495,029	82,823	4,856	(41,790)		540,918
l r- 9r	(2,064)	(39,726)		41,790		
	<u>492,965</u>	<u>43,097</u>	<u>4,856</u>			<u>540,918</u>
9r 9r						
A 9	232,722	27,390	4,856			264,968
O r	<u>260,243</u>	<u>15,707</u>				<u>275,950</u>
	<u>492,965</u>	<u>43,097</u>	<u>4,856</u>			<u>540,918</u>
EBI DA	29,719	(403,995)	168	(4,320)		(378,428)
D r	(22,802)	(1,559)	(33)		(325)	(24,719)
A r	(3,844)	(4,766)			(21)	(8,631)
F ()/	<u>(1,412)</u>	<u>(81)</u>	<u>(14)</u>		5,512	4,005
					<u>(43,790)</u>	<u>(43,790)</u>
Pr /() r	<u>1,661</u>	<u>(410,401)</u>	<u>121</u>	(4,320)	(38,624)	(451,563)

(Expressed in RMB unless otherwise indicated)

6 OTHER GAINS/(LOSSES), NET

		Six months ended 30 June	
		2023	2022
		RMB'000	MB'000
N	r	(91,772)	(26,685)
N	r	222,920	
N	r	1,980	3,476
O	r	(3,224)	(11,853)
	F, PL	<u>129,904</u>	<u>(35,062)</u>

7 FINANCE INCOME AND COSTS

		Six months ended 30 June	
		2023	2022
		RMB'000	MB'000
Finance income			
I	r	2,325	2,119
I	r	1,652	1,807
F	r	383	4,168
		<u>4,360</u>	<u>8,094</u>
Finance costs			
I	r	(1,295)	(1,656)
F	r	(2,136)	(2,136)
O	r	(191)	(297)
		<u>(3,622)</u>	<u>(4,089)</u>

8 INCOME TAX

The Company is subject to income tax in the Cayman Islands, Hong Kong, the PRC and the United States. The Cayman Islands income tax rate is 25% (2022: 15%). The Hong Kong income tax rate is 16.5% (2022: 16.5%). The PRC Corporate Income Tax ("CIT") rate is 25% (2022: 25%).

		Six months ended 30 June	
		2023	2022
		RMB'000	MB'000
Current tax		(24,666)	(6,851)
Deferred tax	(N/A)	1,610	21,121
		<u>(23,056)</u>	<u>14,270</u>

(a) Cayman Islands Income Tax

The Company is subject to income tax in the Cayman Islands. The Cayman Islands income tax rate is 25% (2022: 15%).

(b) Hong Kong Profits Tax

The Company is subject to income tax in Hong Kong. The Hong Kong income tax rate is 16.5% (2022: 16.5%).

(c) PRC Corporate Income Tax ("CIT")

The Company is subject to income tax in the PRC. The PRC Corporate Income Tax ("CIT") rate is 25% (2022: 25%).

* For identification purpose only

(Expressed in RMB unless otherwise indicated)

8 INCOME TAX c ~~1/1~~ued

(d) Withholding Tax

	2023	2022
Withholding tax	(1,234,567)	(1,234,567)
Income tax expense	10%	10%
Income tax payable		

9 EARNINGS/(LOSSES) PER SHARE

(a) Basic earnings/(losses) per share

	2023	2022
Basic earnings/(losses) per share		
Weighted average number of shares		

Six months ended 30 June

	2023	2022
Basic earnings/(losses) per share	126,218	(427,562)
Weighted average number of shares	138,194	138,194
Basic earnings/(losses) per share	0.91	

9 EARNINGS/(LOSSES) PER SHARE ~~in RMB~~

(b) Diluted earnings/(losses) per share ~~in RMB~~

		Six months ended 30 June 2023 RMB'000
	Profit/(loss) attributable to equity holders of the Company	126,218
	Net income	222,920
	Net loss	(91,772)
	Profit/(loss) attributable to equity holders of the Company	(4,930)
	Profit/(loss) attributable to equity holders of the Company	138,194
	Profit/(loss) attributable to equity holders of the Company	64,694
	Profit/(loss) attributable to equity holders of the Company	202,888
	Diluted earnings/(losses) per share (RMB)	(0.02)

Diluted earnings/(losses) per share for the six months ended 30 June 2023, is RMB (0.02) compared with RMB (0.02) for the six months ended 30 June 2022.

(Expressed in RMB unless otherwise indicated)

10 PROPERTY AND EQUIPMENT

	Buildings RMB'000	Leasehold improvements RMB'000	Medical equipment RMB'000	Office equipment, furniture and motor vehicles RMB'000	Construction- in-progress RMB'000	Total RMB'000
Six months ended 30 June 2023						
Balance at 1 January 2023	110,231	16,179	82,749	8,623	1,151	218,933
Acquisition	-	375	1,888	778	-	3,041
Disposal	-	-	(1,404)	(459)	-	(1,863)
Transfer	-	339	-	-	(339)	-
Depreciation	(4,499)	(2,343)	(13,072)	(3,526)	-	(23,440)
Closing amount as at 30 June 2023	105,732	14,550	70,161	5,416	812	196,671
Six months ended 30 June 2022						
Balance at 1 January 2022	118,239	15,571	104,592	11,563	750	250,715
Acquisition	-	3,063	1,477	788	-	5,328
Transfer	-	356	-	-	(356)	-
Disposal	(3,743)	(2,784)	(14,061)	(2,812)	-	(23,400)
Closing amount as at 30 June 2022	114,496	16,206	92,008	9,539	394	232,643

E E A D E D E A C A A

(Expressed in RMB unless otherwise indicated)

(Expressed in RMB unless otherwise indicated)

12 INTANGIBLE ASSETS

		Goodwill RMB'000	Contractual rights to provide management services RMB'000	Licenses RMB'000	Software RMB'000	Total RMB'000
Six months ended 30 June 2023						
NON-CONTROLLING INTERESTS						
Opening balance	1 January 2023	745,868	258,743	153,431	4,195	1,162,237
Acquisition		-	-	-	499	499
Amortisation		-	(3,702)	(3,237)	(770)	(7,709)
Closing balance	30 June 2023	<u>745,868</u>	<u>255,041</u>	<u>150,194</u>	<u>3,924</u>	<u>1,155,027</u>
Six months ended 30 June 2022						
NON-CONTROLLING INTERESTS						
Opening balance	1 January 2022	1,108,690	364,617	159,905	4,096	1,637,308
Acquisition		-	(4,710)	(3,237)	207	207
Impairment		(362,822)	(97,461)	-	(212)	(8,159)
Closing balance	30 June 2022	<u>745,868</u>	<u>262,446</u>	<u>156,668</u>	<u>4,091</u>	<u>1,169,073</u>

13 TRADE RECEIVABLES

r r

	As at 30 June 2023 RMB'000	31 D r	A 2022 MB'000

(Expressed in RMB unless otherwise indicated)

14 BALANCES WITH RELATED PARTIES

(a) Amounts due from related parties

As at 30 June 2023 31 December 2022, RMB'000

	As at 30 June 2023 RMB'000	As at 31 December 2022 RMB'000
Amounts due from related parties		
(Zhejiang Jinhua Gufu Tumor Hospital)	163,112	154,022
*(Cixi Honghe Hospital)	9,414	5,999
*(Yongkang Hospital)	822	854
	173,348	160,875
Other receivables	100,000	100,000
▼ Other receivables	378	365
	7	7
	273,733	261,247

As at 30 June 2023 31 December 2022, RMB'000

14 BALANCES WITH RELATED PARTIES *c / d*

(a) Amounts due from related parties *c / d*

As at 30 June 2023 31 December 2022,

90
180
180

As at 30 June 2023 RMB'000	A 31 December 2022 MB'000
14,507	11,311
4,206	478
154,635	149,086
173,348	160,875

(b) Amounts due to related parties

Amounts due to related parties

J H
O
J H
G
C H

As at 30 June 2023 RMB'000	A 31 December 2022 MB'000
-	3,145
6,028	6,028
1,563	1,514
70	70
7,661	10,757

(Expressed in RMB unless otherwise indicated)


15 CASH AND CASH EQUIVALENTS

	As at 30 June 2023 RMB'000	A 31 D 2022 MB'000
C	341,821	254,032
C	299	1,496
r	29,220	28,933
D	221,600	212,600
	<u>592,940</u>	<u>497,061</u>

16 TRADE PAYABLES

	As at 30 June 2023 RMB'000	A 31 D 2022 MB'000
90	111,763	119,820
91 180	7,419	8,383
181 1 r	8,386	3,775
O r 1 r	4,388	4,877
	<u>131,956</u>	<u>136,855</u>





(Expressed in RMB unless otherwise indicated)

18 BORROWINGS

A 30 J 2023 31 D 2022, Gr ' r r r :

Bank borrowings

As at	A
30 June	31 D
2023	2022
RMB'000	MB'000
46,600	69,429

1 r

19 CONVERTIBLE BONDS

C r r 2018 2019, r r
r r r r .
r r :

Convertible Bonds

MB'000

A 1 J r 2023	1,026,407
A r	(763)
F r	(130,385)
A 30 J 2023	<u>895,259</u>
A 1 J r 2022	906,916
A r	(763)
F r	<u>27,448</u>
A 30 J 2022	<u>933,601</u>

O 6 J 2023, r r r r r r
r r , Gr r H C F III (C), L.P.
r r r r r r
r G r , r r r r r r
(D A). P r D A , () r r 5
M r 2018 r 29 D r 2023 30 r r 2025; () r
r r 7 A 2018 r 7 A 2023 30 r
2025. r D A , r r

N r r r r r C r
30 J 2023.

19 CONVERTIBLE BONDS *continued*

	As at 30 June 2023 RMB'000	31 D 2022 MB'000
▼	29%	12%

(Expressed in RMB unless otherwise indicated)

20 DEFERRED INCOME TAX *continued*

Deferred income tax assets

	Provisions MB'000	Changes in fair value MB'000	Lease liabilities MB'000	Total MB'000
Balance at 1 January 2023	9,264	48	–	9,312
Cr / (Dr)	(82)	–	109	27
Balance at 30 June 2023	9,182	48	109	9,339
Balance at 1 January 2022	9,236	48		9,284
Cr / (Dr)	(224)			(224)
Balance at 30 June 2022	9,012	48		9,060

Deferred income tax liabilities

	Fair value adjustments on buildings and intangible assets and subsequent depreciation, Amortisation and impairment RMB'000	Withholding tax RMB'000	Interest capitalisation and subsequent depreciation RMB'000	Depreciation charge of right-of-use assets RMB'000	Total RMB'000
Balance at 1 January 2023	(111,752)	(38,941)	(363)	–	(151,056)
Cr / (Dr)	1,913	–	12	(342)	1,583
Balance at 30 June 2023	(109,839)	(38,941)	(351)	(342)	(149,473)

20 DEFERRED INCOME TAX *c / d*

Deferred income tax liabilities *c / d*

	31 December 2022		30 June 2022		30 June 2023	
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000
Balance at 1 January 2022	(139,413)	(38,941)	(387)		(178,741)	
Change during the period	26,211	(4,878)	12		21,345	
Balance at 30 June 2022	(113,202)	(43,819)	(375)		(157,396)	
At 30 June 2023, MB122,730,000						MB12,273,000

22 SIGNIFICANT RELATED PARTY TRANSACTIONS *continued*

(a) Significant transactions with related parties

	Six months ended 30 June	
	2023 RMB'000	2022 MB'000
M J H C H	– 8,733	4,656 10,534
	<u>8,733</u>	<u>15,190</u>
 C H J H H	645 23,706 284	1,822 22,731 3,202
	<u>24,635</u>	<u>27,755</u>
 P r D M E M C , L C , L	– – –	6,631 3,946 –
	<u>–</u>	<u>10,577</u>

(b) Loans from related parties

	Six months ended 30 June	
	2023 RMB'000	2022 MB'000
B L O r	7,612 – 49	7,376 43 73
	<u>7,661</u>	<u>7,492</u>

22 SIGNIFICANT RELATED PARTY TRANSACTIONS *continued*

(c) Loans to related parties

	Six months ended 30 June	
	2023 RMB'000	2022 MB'000
B	100,373	80,350
L	-	20,000
I	2,465	2,246
I	(2,465)	(1,020)
O	12	16
	<u>100,385</u>	<u>101,592</u>

(d) Key management compensation

	Six months ended 30 June	
	2023 RMB'000	2022 MB'000
,	4,217	4,689
,	230	204
	<u>4,447</u>	<u>4,893</u>

(e) Provide guarantee for related party

A	30 J	2023, I	-	-
H		M	C ., L .*(浙江弘和致遠醫療科技有限公司)(H	